Zemplar and Repaglinide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Zemplar (paricalcitol) and Repaglinide (repaglinide). Common drug interactions include anaemia among females and arteriosclerosis among males.

The phase IV clinical study analyzes what interactions people have when they take Zemplar and Repaglinide. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Zemplar?

Zemplar has active ingredients of paricalcitol. It is often used in kidney disease. eHealthMe is studying from 15,494 Zemplar users. Check the latest studies of Zemplar.

What is Repaglinide?

Repaglinide has active ingredients of repaglinide. It is often used in diabetes. eHealthMe is studying from 8,226 Repaglinide users. Check the latest studies of Repaglinide.

On Jul, 21, 2026

15 people who take Zemplar and Repaglinide together, and have interactions are studied.

Zemplar and Repaglinide drug interactions.

What are the common drug interactions of Zemplar and Repaglinide, by gender? *:

female:

Anaemia (lack of blood)
Cardiac failure congestive
Cardiopulmonary failure (cessation of normal circulation of the blood due to failure of the heart to contract)
Diarrhoea
Hypotension (abnormally low blood pressure)
Pneumonia
Renal failure chronic (long lasting kidney dysfunction)
Sepsis (a severe blood infection that can lead to organ failure and death)
Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin)
Tachycardia (a heart rate that exceeds the range of 100 beats/min)

male:

Arteriosclerosis (thickening and hardening of arteries)
Cardiac arrest
Fall
Haemorrhage intracranial (bleeding within the skull)
Quadriplegia (a four limb paralysis)
Cardiac failure
Angina unstable (chest pain due to ischemia of the heart muscle- unstable)
Cardiac enzymes increased
Chronic kidney disease
Dyspnoea (difficult or laboured respiration)

What are the common drug interactions of Zemplar and Repaglinide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Graft loss (graft failure)
Pneumonia
Transplant rejection (a transplant material is not worked)

50-59:

Apnoea (suspension of external breathing)
Brain oedema (excess accumulation of fluid in the intracellular or extracellular spaces of the brain)
Fall
Haemorrhage intracranial (bleeding within the skull)
Quadriplegia (a four limb paralysis)

60+:

Arteriosclerosis (thickening and hardening of arteries)
Cardiac arrest
Chest pain
Diarrhoea
Hypotension (abnormally low blood pressure)
Pneumonia
Renal failure (kidney dysfunction)
Renal failure chronic (long lasting kidney dysfunction)
Sepsis (a severe blood infection that can lead to organ failure and death)
Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin)

What are the existing conditions these people have? *

Hyperparathyroidism (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium): 4 people, 26.67%
High Blood Cholesterol: 4 people, 26.67%
High Blood Pressure: 4 people, 26.67%
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 3 people, 20.00%
Blood Glucose Increased: 3 people, 20.00%
Cough: 3 people, 20.00%
Eye Infection: 3 people, 20.00%
Gastritis (inflammation of stomach): 3 people, 20.00%
Itching: 3 people, 20.00%
Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 3 people, 20.00%

* Approximation only. Some reports may have incomplete information.

Do you take Zemplar and Repaglinide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously